Advanced Oesophageal Cancer Study to Compare Quality of Life and Palliation of Dysphagia.
NCT00193882
Completed
To compare the treatment of gullet cancer with radiotherapy alone and assess the advantage and toxicity of adding chemotherapy. The hypothesis to be tested is as follows: That the addition of chemotherapy to a short course of radiation treatment improves the proportion of patients who achieve relief of dysphagia and improves quality of life compared to radiation alone in patients with advanced oesophageal cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/10/2017
Locations: Liverpool Hospital, Liverpool, New South Wales +24 locations
Conditions: Esophagus Cancer
Register for Updates
Cancer Immunotherapy GSK1572932A as Adjuvant Therapy for Patients With Tumor-antigen-positive Non-Small Cell Lung Cancer
NCT00455572
Terminated
The purpose of this clinical trial is to find out how successfully non-small-cell lung cancer patients are able to give an immune response to injections of the immunotherapeutic product GSK1572932A, and to find out more about the safety of this treatment. A course of eight injections will be administered over 21 weeks; including screening for suitability and all tests, the duration of the study for a patient will be 30-35 weeks. During this period various tests will be performed, including physi... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/12/2017
Locations: GSK Investigational Site, Genk, Not set +25 locations
Conditions: Lung Cancer, Non-Small Cell
Register for Updates
Determination of Cetuximab Versus Cisplatin Early and Late Toxicity Events in HPV+ OPSCC
NCT01874171
Unknown
Oropharyngeal squamous cell carcinoma (OPSCC) incidence is increasing rapidly in the developed world. This has been attributed to a rise in Human Papillomavirus (HPV) infection. HPV+OPSCC is considered a distinct disease entity, affecting younger patients and has a good prognosis following treatment. Subsequently, patients can live with the considerable side effects for several decades. Radiotherapy and cetuximab (Epidermal Growth Factor Receptor-inhibitor) have demonstrated similar efficacy to... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/04/2017
Locations: St Luke's Hospital, Dublin, Not set +32 locations
Conditions: Oropharyngeal Squamous Cell Carcinoma
Register for Updates
E7050 in Combination With Cisplatin and Capecitabine Versus Cisplatin and Capecitabine Alone in Patients With Advanced or Metastatic Solid Tumors and Previously Untreated Gastric Cancer
NCT01355302
Terminated
The purpose of this study is to determine the following: 1. Find the maximum tolerated dose of E7050 when given in combination with cisplatin and capecitabine in patients with advance or metastatic solid tumors, and 2) Whether E7050 in combination with cisplatin and capecitabine is more effective in patients with previously untreated gastric cancer versus cisplatin and capecitabine alone.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/07/2017
Locations: Arizona Oncology Associates, PC - CASA, Tucson, Arizona +18 locations
Conditions: Advanced or Metastatic Solid Tumors, Previously Untreated Gastric Cancer
Register for Updates
Study of Lurbinectedin (PM01183) in Combination With Cisplatin in Patients With Solid Tumors
NCT01980667
Completed
Clinical and Pharmacokinetic Study of Lurbinectedin (PM01183) in Combination with Cisplatin in Patients with Advanced Solid Tumors to determine the recommended dose (RD) of PM01183 in combination with cisplatin, to characterize the safety profile, the pharmacokinetics (PK) of this combination, to obtain preliminary information on the clinical antitumor activity and to conduct an exploratory pharmacogenomic (PGx) analysis.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/25/2017
Locations: Not set, Bellinzona, Not set +2 locations
Conditions: Advanced Solid Tumors
Register for Updates
Phase IIB/III Of TG4010 Immunotherapy In Patients With Stage IV Non-Small Cell Lung Cancer
NCT01383148
Terminated
This is a Phase IIb/III randomized, double-blind, placebo-controlled study to compare the efficacy and safety of first-line therapy combined with TG4010 or placebo in stage IV non-small cell lung cancer (NSCLC). TG4010 is a suspension of recombinant Modified Vaccinia virus strain Ankara (MVA strain) carrying coding sequences for human MUC1 antigen and human interleukin-2 (IL2). TG4010 has been developed for use as an immunotherapy in cancer patients whose tumors express the MUC1 antigen. TG401... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/04/2017
Locations: Mayo Clinic Arizona, Scottsdale, Arizona +71 locations
Conditions: Non-Small-Cell Lung Carcinoma
Register for Updates
Chemotherapy Followed By Surgery Vs Radiotherapy Plus Chemotherapy in Patients With Stage IB or II Cervical Cancer
NCT00039338
Unknown
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving chemotherapy drugs before surgery may shrink the tumor so that it can be removed during surgery. Radiation therapy uses high-energy x-rays to kill tumor cells. Combining radiation therapy with chemotherapy may kill more tumor cells. It is not yet known whether chemotherapy is more effective followed by surgery or combined with radiation therapy in treating cervical cance... Read More
Gender:
FEMALE
Ages:
Between 18 years and 75 years
Trial Updated:
12/02/2016
Locations: Karl-Franzens-University Graz, Graz, Not set +23 locations
Conditions: Cervical Cancer
Register for Updates
Chemotherapy With or Without Bevacizumab or Lapatinib to Treat Operable Oesophagogastric Cancer
NCT00450203
Unknown
RATIONALE: Drugs used in chemotherapy, such as epirubicin, cisplatin, and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as bevacizumab, and small molecule tyrosine kinase inhibitors, such as lapatinib, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to t... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/30/2016
Locations: Royal Bournemouth Hospital, Bournemouth, England +40 locations
Conditions: Oesophagogastric Cancer
Register for Updates
A Study of Avastin (Bevacizumab) in Combination With Thoracic Radiation and Chemotherapy in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer.
NCT00776698
Completed
This single arm study will evaluate the feasibility of treatment with 2 dose levels of Avastin in combination with concurrent thoracic radiation and chemotherapy in patients with locally advanced unresectable non-squamous non-small cell lung cancer. Two cohorts of patients will receive 3 cycles of Avastin treatment (7.5mg/kg and 15mg/kg iv every 3 weeks, respectively), concurrently with thoracic radiation and chemotherapy (cisplatin and etoposide). Once a preferred dose has been established, thi... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/01/2016
Locations: Not set, Amsterdam, Not set +4 locations
Conditions: Non-Squamous Non-Small Cell Lung Cancer
Register for Updates
A Study of Avastin (Bevacizumab) in Patients With Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
NCT00806923
Completed
This 3 arm study will evaluate the efficacy and safety of adding Avastin versus placebo to a standard chemotherapeutic regimen in patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC) who have not received prior chemotherapy. The anticipated time of study treatment is until disease progression, and the target sample size is 500+ individuals.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/01/2016
Locations: Not set, Bahia Blanca, Not set +153 locations
Conditions: Non-Squamous Non-Small Cell Lung Cancer
Register for Updates
A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer
NCT01450696
Terminated
This randomized, open-label, multicenter, international Phase IIIb study will compare the efficacy and safety of two Herceptin dosing regimens in combination with cisplatin/capecitabine chemotherapy in participants with HER2-positive metastatic gastric or gastro-esophageal junction adenocarcinoma. Participants who have not received prior treatment for metastatic disease will be randomized to receive Herceptin intravenously as either an 8-milligram per kilogram (mg/kg) loading dose followed by 6... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/05/2016
Locations: Not set, La Jolla, California +116 locations
Conditions: Gastric Cancer
Register for Updates
A Study of Onartuzumab (MetMAb) in Combination With Bevacizumab (Avastin) Plus Platinum And Paclitaxel or With Pemetrexed Plus Platinum in Patients With Non-Squamous Non-Small Cell Lung Cancer
NCT01496742
Completed
This multicenter, randomized, double-blind, placebo-controlled study will evaluate the efficacy and safety of RO5490258 (MetMab) in combination with either of two backbone chemotherapy regimens in the first-line setting in patients with incurable Stage IIIB or IV non-squamous non-small cell lung cancer. In Cohort 1, patients will be randomized to receive 4 cycles of bevacizumab (Avastin) 15 mg/kg iv, paclitaxel 200 mg/m2 iv, platinum (cisplatin/carboplatin) iv plus either MetMab 15 mg/kg iv or p... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/21/2016
Locations: Not set, Huntsville, Alabama +86 locations
Conditions: Non-Squamous Non-Small Cell Lung Cancer
Register for Updates